The purpose of this study is to provide data on the proportion of seroconverted children and their immune status. It will also provide insight into the number of children currently infected at each time point including healthy carriers. Investigators will provide similar data on their parents in an ancillary study.
The fraction of undiagnosed but likely to transmit the virus is a critical epidemiological
characteristic that modulates the epidemic potential of SARS-CoV2. To adapt the epidemy
control, it is essential to study the immunoprotection of the general population. A crucial
question is the study of pauci or asymptomatic subjects, and in particular children who make
mild forms, because they could act as a real reservoir for the spread of the virus. The
serological study is essential in this context.
The serologic test Abbott will be used to study immunoprevalence. Institut Pasteur has
validated test using neutralizing Ab. CEA will used a antibodies and antigen test.
Biological: serology test
volume according to child weight
Biological: nasopharyngeal swab
nasopharyngeal swab for PCR
Biological: rectal swab
rectal swab for PCR
Biological: saliva sample
for biocollection
Inclusion Criteria:
For hospitalized children or consulting at hospital
- any child over 7 days old and under 17 years old in consultation or hospitalized for
at most 4 days at AP-HP or CH Cayenne; Or any child over 7 days old and under 17 years
old with a positive PCR at home, with an attending physician in a participating centre
- Parent's agreement for blood, saliva and stool samples
- Optional parent's agreement for nasopharynx swab
- Optional parent's agreement for follow-up if PCR+
- With an Health insurance
For children with potential COVID disease during the first wave
- Any child over 7 days old and under 17 years, seropositive during the first wave
- Or any child over 7 days old and under 17 years, with a previous inflammatory clinical
disease potentially linked to SARS-cov2
- With an Health insurance
Parent of the enrolled child
- One parent of the enrolled child on ped-covid
- Agreement for blood and saliva samples
- Optional agreement for nasopharynx swab
- Optional parent's agreement for follow-up if PCR+
- With an Health insurance
For children SARS-coV2 positive
- any child less then 18 years old
- infected by SARS-coV2
- Parent's agreement for blood, saliva samples
- Optional parent's agreement for nasopharynx swab
- With health insurance
For people living under the same roof of a child included in the study
- any child or adult living under the same roof of a child SARS-coV2 positive and
included in the study
- With health insurance
Exclusion Criteria:
For hospitalized children or consulting at hospital
- child younger than 7 days
- Refusal of parent
- Refusal of child
- No health insurance
Hôpital necker Enfants-Malades
¨Paris, France
Isabelle SERMET-GAUDELUS, MD, PhD, Principal Investigator
Assistance Publique-Hôpitaux de Pars